MARKET

MYOS

MYOS

MYOS RENS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.380
+0.010
+0.00%
Closed 16:00 12/10 EST
OPEN
1.380
PREV CLOSE
1.380
HIGH
1.437
LOW
1.380
VOLUME
5.67K
TURNOVER
--
52 WEEK HIGH
2.020
52 WEEK LOW
1.070
MARKET CAP
12.76M
P/E (TTM)
-3.8134
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MYOS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

EPS

MYOS News

  • MYOS to Introduce its Longevity Business with its Physician Muscle Health Formula at the World Congress on Anti-Aging Medicine in Las Vegas December 13-15, 2019
  • PR Newswire.11h ago
  • Edited Transcript of MYOS earnings conference call or presentation 8-Nov-19 3:00pm GMT
  • Thomson Reuters StreetEvents.12/02 10:32
  • MYOS: Q3 2019 Update: Positive Clinical Data, Word-of-Mouth Driving Consumer & Professional Demand
  • Zacks Small Cap Research.11/26 11:55
  • MYOS RENS' Fortetropin® Clinical Trial Results to be Presented by William J. Evans, Ph.D., at the International Conference on Frailty and Sarcopenia Research
  • PR Newswire.11/20 12:27

More

Industry

Food Processing
-0.15%
Food & Tobacco
-0.22%

Hot Stocks

Name
Price
%Change

About MYOS

MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.
More

Webull offers MYOS RENS Technology Inc (MYOS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.